Ind-Swift Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on August 11, 2025.
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ind-Swift Laboratories' board approved audited Q4 and FY25 results (standalone and consolidated), with the merger of Ind-Swift Limited becoming effective on August 8, 2025 under the pooling of interest method, resulting in a capital reserve of Rs. 465.9 crores. Standalone revenue from operations fell sharply to Rs. 549.6 crores in FY25 from Rs. 1,672.6 crores in FY24 on a post-merger restated basis, a YoY decline of roughly 67%. Standalone net profit for FY25 was Rs. 256.1 crores (vs Rs. 536.2 crores in FY24), with large exceptional income of about Rs. 391 crores meaningfully boosting the bottom line. The auditor issued an unmodified opinion but flagged four Emphasis of Matter items: conversion of equity share warrants, the amalgamation scheme, fixed deposit repayment, and the sale of plant, land and buildings at the Baddi units. Operating cash flow stayed negative at around Rs. 39 crores for FY25, and the board allotted 14.2 lakh 1% Redeemable Preference Shares of Rs. 100 each pursuant to the merger.
The restructuring (merger) is now formally complete, but the steep revenue contraction, persistent negative operating cash flow, and heavy reliance on exceptional items to prop up profits suggest underlying operational stress. Shareholders should watch for revenue stabilization and a turnaround in cash generation in coming quarters.